Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Lung Neoplasms × aumolertinib × Clear all

Phase

Status

Unknown 8 Withdrawn 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 7 Rare Tumor 1 Non-small Cell Lung Cancer Metastatic 1 Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor 1 Lung Neoplasms 1 EGFR Tyrosine Kinase Inhibitors Plus Cyclin-dependent Kinase 4/6 Inhibitor 1 Brain Neoplasms 1 Advanced Non-small Cell Lung Cancer 1

Interventions

pembrolizumab 51 Carboplatin 46 Magnetic Resonance Spectroscopy 40 Specimen Handling 38 Pemetrexed 36 Cisplatin 27 Blood Specimen Collection 25 durvalumab 17 Paclitaxel 17 osimertinib 15 Radiosurgery 15 Bevacizumab 15 Radiotherapy 14 Nivolumab 14 Gemcitabine 14 atezolizumab 13 Biopsy 13 Drug Therapy 11 Docetaxel 11 130-nm albumin-bound paclitaxel 11 Immunoglobulin G 10 X-Rays 9 Taxes 9 Standard of Care 9 Practice Guidelines as Topic 9 Etoposide 9 Disulfides 9 tislelizumab 8 Educational Status 8 Cetuximab 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04841811 2023-11-18

APPROACH

Guangdong Association of Clinical Trials

Phase 3 Recruiting

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡